Phase II Study of Tesetaxel in Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Advanced MelanomaCancer
Interventions
DRUG

Tesetaxel

"Cohort A: 40 mg by mouth every 21 days.~Cohort B. 50 mg by mouth every 21 days."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genta Incorporated

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER